-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Public Policy
Latest From Public Policy
Biotech IP Challenges Around the World: BIO’s Special 301 Submission
BIO recently submitted its Special 301 Submission highlighting intellectual property (IP) challenges around the world. In particular, BIO informed the United States Trade Representative (USTR) of the persistent problems biotech companies face with issues including counterfeiting, large backlogs and patent office inefficiency, differing judicial standards for enforcement, compulsory licensing, inadequate data protection, lack of patentability of biotech inventions, overbearing genetic resources access and benefit regimes, technology transfer issues and a great need for international harmonization Read More >
AUTM Website Helps Commercialize University Technologies
By Robin L. Rasor, CLP, RTTP, AUTM President As president of the Association of University Technology Managers (AUTM), I’m in a unique position of hearing from university technology managers who want more opportunity to interact with industry, and industry members who want to identify the latest breakthrough innovations. Industry investors and their academic licensing counterparts already come together for dealmaking at the AUTM Annual Meeting and at the BIO International Convention, but now we have Read More >
Patent Awards for Humanitarian Ventures
The USPTO recently announced the Patents for Humanity Challenge which awards patent owners and licensees for innovations that address humanitarian needs. Judges will chose winners from four categories: Medical technology – includes medicines, vaccines, diagnostic equipment, or assistive devices. Food and nutrition – includes agricultural technology like drought-resistant crops, more nutritious crop strains, farming equipment, and technologies that improve food storage, preservation, or preparation. Clean technology – includes technologies that improve public health by removing Read More >
Is the Polio Vaccine an Anti-Patent Success Story?
By Hans Sauer, Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization Question from a Reader: Heather: Whether Jonas Salk believed in patenting research or not isn’t important, at least not to me. What I do find important, and hadn’t realized until reading this article, is that the polio vaccine was extremely successful despite the fact that it wasn’t patented. That sounds like an interesting story because it goes against the current dogma of ‘we won’t Read More >
The Real Reason Why Salk Refused to Patent the Polio Vaccine
A guest writer in a recent article in the Wall Street Journal repeated the oft quoted Jonas Salk statement about his Polio vaccine: “There is no patent. Could you patent the sun?” Many use this statement as the moral impetus for refusing patents on medically important innovations (see Michael Moore’s Capitalism: A Love Story). Unfortunately, Jonas Salk created a myth that day by leaving out several crucial details. As pointed out by Robert Cook-Deegan at Read More >
